Genentech

Gilead, Genentech join PhRMA
Gilead, Genentech join PhRMA
BioCentury
PhRMA
Genentech
Gilead Sciences
Flag link:
Genentech Cutting More Jobs in Bay Area
Genentech Cutting More Jobs in Bay Area
BioSpace
Genentech
Roche
layoffs
Bay Area
Flag link:
Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal
Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal
BioSpace
Genentech
Proteostasis Therapeutics
small molecule drugs
Flag link:
Genentech develop antibiotic with potential to lead to new class of antibiotics
Genentech develop antibiotic with potential to lead to new class of antibiotics
Pharmaforum
Genentech
G07750
antibiotics
drug development
antibiotic resistance
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
BioSpace
Genentech
FDA
Tecentriq
Avastin
non-squamous cell non-small cell lung cancer
Flag link:
Tecentriq could be first front-line SCLC therapy approved in two decades
Tecentriq could be first front-line SCLC therapy approved in two decades
BioCentury
FDA
Tecentriq
Genentech
extensive-stage small cell lung cancer
Flag link:
Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics
Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics
Xconomy
Roche
Jecure Therapeutics
M&A
NASH
Genentech
Flag link:
FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia
FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia
Yahoo/Guru Focus
Roche
Genentech
Venclexta
FDA
AML
acute myeloid leukemia
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug
Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug
Fierce Biotech
Genentech
Roche
MAGE-A4
IMC-C103C
Immunocore
Flag link:
Roche’s Tecentriq gets fast review in triple negative breast cancer
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Roche
Genentech
Tecentriq
Celgene
Abraxane
FDA
triple negative breast cancer
Flag link:
Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'
Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'
Endpoints
Genentech
Roche
JHL Biotech
trade secrets
Flag link:
Roche and AbbVie Push Towards First-Line CLL Treatment
Roche and AbbVie Push Towards First-Line CLL Treatment
BioSpace
Roche
Genentech
AbbVie
clinical trials
Venclexta
Gazyva
CLL
chronic lymphocytic leukemia
Flag link:
Genentech staff ‘funneled secrets to Taiwan biosimilar firm,’ prosecutors say
Genentech staff ‘funneled secrets to Taiwan biosimilar firm,’ prosecutors say
Fierce Biotech
Genentech
trade secrets
Taiwan
biosimilars
Flag link:
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Roche
Genentech
Regeneron
Novartis
Eylea
faricimab
wet-AMD
Flag link:
Sanofi, Genentech Both Eye U.S. Expansions; Could Add up to 2,300 Jobs
Sanofi, Genentech Both Eye U.S. Expansions; Could Add up to 2,300 Jobs
BioSpace
Sanofi
Cambridge MA
Genentech
Oregon
Flag link:
Roche and Novartis Strengthen Their Presence in the MS Market
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Flag link:
Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic
Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic
Endpoints
Immune-Onc
Genentech
Flag link:
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
BioSpace
FDA
Genentech
Hemlibra
hemophilia
Flag link:

Pages